{"analyses":[{"ciLowerLimit":"0.850","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1,738","estimateComment":"Hazard ratio (anetumab ravtansine / vinorelbine) was estimated using Cox proportional hazards models with Wald CIs, stratified by Time to progression (TTP) on 1st line treatment.","groupDescription":"PFS anetumab ravtansine / vinorelbine","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.859125","pValueComment":"1-sided p-value from log-rank test (stratified by TTP on 1st line treatment). P-value is calculated based on alpha level 0.0125.","paramType":"Hazard Ratio (HR)","paramValue":"1.215","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"5.5","value":"4.3"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"5.8","value":"4.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"Progression-free survival (PFS), defined as time from randomization until disease progression according to mRECIST (Modified Response Evaluation Criteria in Solid Tumors) for Malignant pleural mesothelioma (MPM) per blinded central radiology review, or death. Only descriptive analysis of OS was repeated in the follow-up period.","dispersionType":"95% Confidence Interval","groups":[{"description":"Test drug: 6.5 mg/kg every 3 weeks; Intravenous (IV) infusion over 1 hour","id":"OG000","title":"Anetumab Ravtansine"},{"description":"Active comparator: 30 mg/m\\^2 once weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"MEDIAN","populationDescription":"The primary efficacy analysis (PFS) was performed in the ITT (Intent-to-treat) analysis set.","reportingStatus":"POSTED","timeFrame":"From randomization till approximately 117 PFS events observed, up to approx. 30 months (data cut-off: 31-May-2017)","title":"Progression-free Survival (PFS), [95% CI]","type":"PRIMARY","unitOfMeasure":"months"}